1003-3734
2014 Issue 17
..............page:1963+1966
WINDOW OF NEW DRUGS
ben kan ;
ben kan ;
..............page:1967-1968
Albiglutide:a new anti-diabetic drug of human glucagon-like peptide analogue
CHEN Lan-ting;ZHU Yi-shen;FAN Xue-hai;LI Wen-hui;WEI Ping;The College of Biotechnology and Pharmaceutical Engineering;Nanjing Tech University;
CHEN Lan-ting;ZHU Yi-shen;FAN Xue-hai;LI Wen-hui;WEI Ping;The College of Biotechnology and Pharmaceutical Engineering;Nanjing Tech University;
..............page:1969-1972
Phase 0 clinical trials in the development of oncology new drugs in USA
SHAO Rong;TAO Tian-tian;School of International Pharmaceutical of China Pharmaceutical University;
SHAO Rong;TAO Tian-tian;School of International Pharmaceutical of China Pharmaceutical University;
..............page:1973-1979
Problems in writing production process in production site inspection of new TCM drugs
ZHOU Gang;MA Xiu-jing;HAN Wei;Center for Drug Evaluation;China Food and Drug Administration;
ZHOU Gang;MA Xiu-jing;HAN Wei;Center for Drug Evaluation;China Food and Drug Administration;
..............page:1980-1983+2007
Development prospects of drug toxicology
WANG Quan-jun;YUAN Ye;MA Hua-zhi;LIAO Ming-yang;WU Chun-qi;DING Ri-gao;State Key Laboratory of Toxicology and Medical Countermeasures;National Beijing Center for Drug Safety Evaluation and Research;Institute of Pharmacology and Toxicology;Academy of Military Medical Sciences;
WANG Quan-jun;YUAN Ye;MA Hua-zhi;LIAO Ming-yang;WU Chun-qi;DING Ri-gao;State Key Laboratory of Toxicology and Medical Countermeasures;National Beijing Center for Drug Safety Evaluation and Research;Institute of Pharmacology and Toxicology;Academy of Military Medical Sciences;
..............page:1984-1989
Progress in the methodological study of in vivo Comet assay
OU Hong-mei;ZHOU Chang-hui;TU Hong-gang;CHANG Yan;China State Institute of Pharmaceutical Industry;Shanghai Institute of Pharmaceutical Industry;National Shanghai Center for New Drug Safety Evaluation & Research;
OU Hong-mei;ZHOU Chang-hui;TU Hong-gang;CHANG Yan;China State Institute of Pharmaceutical Industry;Shanghai Institute of Pharmaceutical Industry;National Shanghai Center for New Drug Safety Evaluation & Research;
..............page:1990-1993
Clinical reaserch development of resistance mechanisms of EGFR-TKIs targeted therapy in patients with non-small cell lung cancer
KE E-e;WU Yi-long;Lung Cancer Research Institute;People’s Hospital of Guangdong Province;Academy of Medical Sciences;Guangdong Province;
KE E-e;WU Yi-long;Lung Cancer Research Institute;People’s Hospital of Guangdong Province;Academy of Medical Sciences;Guangdong Province;
..............page:1994-1998
Development of pharmacogenomics for anti-cancer drugs
ZHANG Yan;SHI Yuan-kai;HAN Xiao-hong;Beijing Key Laboratory of Clinical Study on Antitumor Molecular Target Drugs;Department of Medical Oncology;Cancer Institute/Hospital;Chinese Academy of Medical Sciences &Peking Union Medical College;
ZHANG Yan;SHI Yuan-kai;HAN Xiao-hong;Beijing Key Laboratory of Clinical Study on Antitumor Molecular Target Drugs;Department of Medical Oncology;Cancer Institute/Hospital;Chinese Academy of Medical Sciences &Peking Union Medical College;
..............page:1999-2003+2034
Current research on quantitative detection of biomacromolecule drugs
SONG Yuan-yuan;SHI Yuan-kai;Department of Medical Oncology;Cancer Institute/Hospital;Chinese Academy of Medical Sciences & Peking Union Medical College;Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Dugs;
SONG Yuan-yuan;SHI Yuan-kai;Department of Medical Oncology;Cancer Institute/Hospital;Chinese Academy of Medical Sciences & Peking Union Medical College;Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Dugs;
..............page:2004-2007
Current situation and research progress of systemic chemotherapy in the treatment of advanced hepatocellular carcinoma
GONG Xin-lei;QIN Shu-kui;Medical Oncology Department of the;PLA Cancer Center;81 Hospital;
GONG Xin-lei;QIN Shu-kui;Medical Oncology Department of the;PLA Cancer Center;81 Hospital;
..............page:2008-2017
A new era of melanoma therapy
GUO Jun;Key Laboratory of Carcinogenesis and Translational Research;Department of Renal Cancer and Melanoma;Peking University Cancer Hospital & Institute;
GUO Jun;Key Laboratory of Carcinogenesis and Translational Research;Department of Renal Cancer and Melanoma;Peking University Cancer Hospital & Institute;
..............page:2018-2025
Status of chemotherapy in the treatment of advanced prostate cancer
ZHOU Ai-ping;MA Jian-hui;Cancer Hospital;Chinese Academy of Medical Sciences & Peking Union Medical College;
ZHOU Ai-ping;MA Jian-hui;Cancer Hospital;Chinese Academy of Medical Sciences & Peking Union Medical College;
..............page:2026-2029
New progress in research of drugs for advanced prostate cancer
GUAN Kao-peng;LI Chang-ling;Department of Urology;Cancer Institute & Hospital;Chinese Academy of Medical Sciences;Beijing Union Medical College;
GUAN Kao-peng;LI Chang-ling;Department of Urology;Cancer Institute & Hospital;Chinese Academy of Medical Sciences;Beijing Union Medical College;
..............page:2030-2034
Research highlights in medication for gastric cancer from the 2014 ASCO Annual Meeting
LI Zhe-min;JI Jia-fu;Key Laboratory of Carcinogenesis and Translational Research;Department of Gastrointestinal Surgery;Peking University Cancer Hospital & Institute;
LI Zhe-min;JI Jia-fu;Key Laboratory of Carcinogenesis and Translational Research;Department of Gastrointestinal Surgery;Peking University Cancer Hospital & Institute;
..............page:2035-2038+2042
Current status of tumor immunotherapy
JIAO Shun-chang;Department of Oncology;Chinese;PLA General Hospital;
JIAO Shun-chang;Department of Oncology;Chinese;PLA General Hospital;
..............page:2039-2042
Research progress of preoperative neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma
WANG Xi;HUANG Jing;Department of Medical Oncology;Cancer Hospital and Institute;Chinese Academy of Medical Sciences and Peking Union Medical College;
WANG Xi;HUANG Jing;Department of Medical Oncology;Cancer Hospital and Institute;Chinese Academy of Medical Sciences and Peking Union Medical College;
..............page:2043-2047
Cardiotoxicity of anticancer drugs and the prevention and treatment
ZHANG Yan;WANG Yan;Cancer Institute & Hospital;Chinese Academy of Medical Sciences;Beijing Union Medical College;
ZHANG Yan;WANG Yan;Cancer Institute & Hospital;Chinese Academy of Medical Sciences;Beijing Union Medical College;
..............page:2048-2051+2056
Progress in research of drugs targeting PARP for cancer therapy
QIN Zhen;WU Yi-yuan;LUO Lu-song;WANG Lai;WEI Min;BeiGene Co.;Ltd;
QIN Zhen;WU Yi-yuan;LUO Lu-song;WANG Lai;WEI Min;BeiGene Co.;Ltd;
..............page:2052-2056
Cancer pain:where we are,what the problem is and how is the future
WANG Xiang;NING Xiao-hong;Peking Union Medical College;Chinese Academy of Medical Sciences;Peiking Union Medical College Hospital;
WANG Xiang;NING Xiao-hong;Peking Union Medical College;Chinese Academy of Medical Sciences;Peiking Union Medical College Hospital;
..............page:2057-2060+2065
Development of long-circulating thermosensitive liposomes for tumor therapy
TIAN Wei;LI Yin-gui;XIU Xian;ZHEN Ya-qin;LI Chun-lei;School of Pharmacy;Hebei Medical University;CSPC Zhongqi Pharmaceutical Technology Co.;Ltd.;State Key Lab of Novel Pharmaceutical Preparations and Excipients;
TIAN Wei;LI Yin-gui;XIU Xian;ZHEN Ya-qin;LI Chun-lei;School of Pharmacy;Hebei Medical University;CSPC Zhongqi Pharmaceutical Technology Co.;Ltd.;State Key Lab of Novel Pharmaceutical Preparations and Excipients;
..............page:2061-2065
Protective effect of ulinastatin on lung injury in patients with non-small cell lung cancer after radiation therapy
BAO Peng-tao;ZHAO Wei-guo;LI Yun;LIU Yu;ZHOU Yi;TANG Li-ping;Department of Respiratory Pulmonology;The 309th Hospital of PLA;
BAO Peng-tao;ZHAO Wei-guo;LI Yun;LIU Yu;ZHOU Yi;TANG Li-ping;Department of Respiratory Pulmonology;The 309th Hospital of PLA;
..............page:2066-2070
Antitumor and anti-angiogenic effects of isomalto oligosaccharide on human hepatocellular carcinoma HepG2 xenografts in nude mice
LI Hong-yi;CHEN Peng-cheng;CHEN Xue-fei;LI He-sheng;HUA Wen-da;HUANG Lei;Beijing Hospital of the Ministry of Health;First Hospital of Tsinghua University;Binzhou Medical University Hospital of Shandong Province;First Affiliated Hospital of Kunming Medical University;Peking University People’s Hospital;
LI Hong-yi;CHEN Peng-cheng;CHEN Xue-fei;LI He-sheng;HUA Wen-da;HUANG Lei;Beijing Hospital of the Ministry of Health;First Hospital of Tsinghua University;Binzhou Medical University Hospital of Shandong Province;First Affiliated Hospital of Kunming Medical University;Peking University People’s Hospital;
..............page:2071-2076
..............page:2076
Optimized compatibility of anticancer monomers from Venenum Bufonis by uniform design
YANG Shuang;MA Xiao-bing;ZHANG Bo;Department of Pharmacy;Shenyang Medical College Affiliated Central Hospital;Department of Instrument;The People’s Liberation Army No.205 Hospital;Zhongshan School of Medic;Sun Yat-Sen University;
YANG Shuang;MA Xiao-bing;ZHANG Bo;Department of Pharmacy;Shenyang Medical College Affiliated Central Hospital;Department of Instrument;The People’s Liberation Army No.205 Hospital;Zhongshan School of Medic;Sun Yat-Sen University;
..............page:2077-2080
..............page:2080
Pharmaceutical care for hypersensitivity reactions of oxaliplatin
CHEN Zhe;DAI Yuan-yuan;LI Guo-hui;Cancer Hospital;Chinese Academy of Medical Sciences;
CHEN Zhe;DAI Yuan-yuan;LI Guo-hui;Cancer Hospital;Chinese Academy of Medical Sciences;
..............page:2081-2084+2088
Analysis of 112 patients with adverse drug reactions induced by gemcitabine
QIU Shuang;CUI Xiang-li;WANG Ying;Department of Pharmacy;Beijing Chaoyang Hospital Affiliated to Capital Medical University;
QIU Shuang;CUI Xiang-li;WANG Ying;Department of Pharmacy;Beijing Chaoyang Hospital Affiliated to Capital Medical University;
..............page:2085-2088
..............page:2089-2090